Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Peptidase Inhibition and Analysis
TopicLeading institutions, researchers & key papers
This cluster of papers explores the role of fibroblast activation in cancer progression, focusing on the expression of fibroblast activation protein, immunosuppression in the tumor microenvironment, N-terminal acetylation of proteins, protease inhibitors for cancer therapy, angiogenesis, and PET imaging to target stromal cells in the tumor microenvironment.
278
Works
IDs:OpenAlex
How has Peptidase Inhibition and Analysis's publication output changed over time?
ScholarIQpublication output · 2005–2021
Output declined50% over the shown period — from 2 works in 2005 to 1 in 2021.
2
1
1
1
1
2
1
1
1
1
2005200720082009201220132014201520202021
What are the most-cited papers on Peptidase Inhibition and Analysis?
ScholarIQmost cited works
(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes
Dooseop Kim, Liping Wang, Maria Beconi, George J. Eiermann, Michael H. Fisher, Huaibing He, Gerard J. Hickey, Jennifer E. Kowalchick, Barbara Leiting, Kathryn A. Lyons, Frank Marsilio, Margaret E. McCann, Reshma A. Patel, Aleksandr Petrov, Giovanna Scapin, Sangita B. Patel, Ranabir Sinha Roy, Joseph K. Wu, Matthew J. Wyvratt, Bei B. Zhang, Lan Zhu, Nancy A. Thornberry, Ann E. Weber
S162030435. 2004818 CitationsOPEN ACCESS
Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26
Guangwen Lu, Yawei Hu, Qihui Wang, Jianxun Qi, Feng Gao, Yan Li, Yanfang Zhang, Wei Zhang, Yuan Yuan, Jinku Bao, Buchang Zhang, Yi Shi, Jinghua Yan, George F. Gao
Nature. 2013763 CitationsOPEN ACCESS
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
Masanori Asakura, Masafumi Kitakaze, Seiji Takashima, Yulin Liao, Fuminobu Ishikura, Tsuyoshi Yoshinaka, Hiroshi Ohmoto, Koichi Node, Kohichiro Yoshino, Hiroshi Ishiguro, Hiroshi Asanuma, Shoji Sanada, Yasushi Matsumura, Hiroshi Takeda, Shintaro Beppu, Michihiko Tada, Masatsugu Hori, Shigeki Higashiyama
Nature Medicine. 2002722 Citations
Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer
Haojun Chen, Yizhen Pang, Jingxun Wu, Liang Zhao, Bing Hao, Jing Wu, Jihong Wei, Siming Wu, Long Zhao, Zuoming Luo, Xuehua Lin, Chengrong Xie, Long Sun, Qin Lin, Hua Wu
S191349260. 2020548 Citations
The moonlighting enzyme CD13: old and new functions to target
Paola Mina‐Osorio
S64855341. 2008410 CitationsOPEN ACCESS
Where is Peptidase Inhibition and Analysis research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Peptidase Inhibition and Analysis is open access?
ScholarIQopen access share
73%OPEN ACCESS
Gold
7%
Green
27%
Hybrid
13%
Bronze
27%
Closed
27%
Related on ScholarIQ
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Paper
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Paper
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Paper
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Paper
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Paper
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Paper